Wang X, Luo LX. New targets for cancer promotion and therapy in gliomas: Scinderin. World J Clin Oncol 2024; 15(6): 687-690 [PMID: 38946838 DOI: 10.5306/wjco.v15.i6.687]
Corresponding Author of This Article
Lian-Xiang Luo, PhD, Adjunct Associate Professor, The Marine Biomedical Research Institute, Guangdong Medical University, No. 2 Wenming East Road, Zhanjiang 524000, Guangdong Province, China. luolianxiang321@gdmu.edu.cn
Research Domain of This Article
Cell Biology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Oncol. Jun 24, 2024; 15(6): 687-690 Published online Jun 24, 2024. doi: 10.5306/wjco.v15.i6.687
New targets for cancer promotion and therapy in gliomas: Scinderin
Xi Wang, Lian-Xiang Luo
Xi Wang, The First Clinical College, Guangdong Medical University, Zhanjiang 524023, Guangdong Province, China
Lian-Xiang Luo, The Marine Biomedical Research Institute, Guangdong Medical University, Zhanjiang 524000, Guangdong Province, China
Author contributions: Luo LX conceived and designed the editorial, contributed to the topic selection, outline formulation, and finalization of the editorial, reviewed the paper and provided comments; Wang X wrote the editorial; and all authors read and approved the final manuscript.
Conflict-of-interest statement: The author reports no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Lian-Xiang Luo, PhD, Adjunct Associate Professor, The Marine Biomedical Research Institute, Guangdong Medical University, No. 2 Wenming East Road, Zhanjiang 524000, Guangdong Province, China. luolianxiang321@gdmu.edu.cn
Received: January 3, 2024 Revised: April 27, 2024 Accepted: May 20, 2024 Published online: June 24, 2024 Processing time: 173 Days and 7.5 Hours
Abstract
Glioma is one of the most common primary intracranial tumors, characterized by invasive growth and poor prognosis. Actin cytoskeletal rearrangement is an essential event in tumor cell migration. Scinderin (SCIN), an actin severing and capping protein that regulates the actin cytoskeleton, is involved in the proliferation and migration of certain cancer cells. However, its biological role and molecular mechanism in glioma remain unclear. Lin et al explored the role and mechanism of SCIN in gliomas. The results showed that SCIN mechanically affected cytoskeleton remodeling and inhibited the formation of lamellipodia via RhoA/FAK signaling pathway. This study identifies the cancer-promoting role of SCIN and provides a potential therapeutic target for SCIN in glioma treatment.
Core Tip: The role of scinderin (SCIN) in cancer progression has been studied, but its role in glioma remains unknown. Lin et al found that the expression level of SCIN mRNA was positively correlated with the tumor grade of glioma. SCIN affected cytoskeletal remodeling and inhibited lamellipodia formation through RhoA/FAK signaling pathway, thereby facilitating the migration and invasion of glioma cells.
